ALB and chronic kidney disease: Although a recent randomized controlled trial “The ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) study” is designed to determine whether statin exerts protective effects on renal function including estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) in CKD patients with dyslipidemia, the main results have not been reported yet [12].